Literature DB >> 8104329

p53 oncogene mutations in three human prostate cancer cell lines.

A G Carroll1, H J Voeller, L Sugars, E P Gelmann.   

Abstract

p53 gene structure and chromosome 17p alleles were studied in the three human prostate cancer cell lines, LNCaP, DU-145, and PC-3. Our laboratory has two separate culture lines of the LNCaP human prostate cancer cells. One strain, LNCaP-GW, had a mutation in one of two alleles at position 273 (arg > his). This mutation could not be detected in a second strain of LNCaP, LNCaP-ATCC. Immunohistochemical staining for P53 protein in the cell lines indicated that protein overexpression in LNCaP was heterogeneous, even in clonal isolates derived from LNCaP-GW that contained the codon 273 mutation in every cell. We also performed in vitro and in vivo growth analysis to compare the LNCaP-GW and LNCaP-ATCC cells. LNCaP-GW grew more rapidly than LNCaP-ATCC in vitro. However, LNCaP-ATCC formed tumors efficiently when inoculated into nude mice, whereas LNCaP-GW formed tumors much less efficiently. Consideration must be given to the notion that some of these p53 mutations arose during in vitro passage. We also confirmed published findings with two other human prostate cancer cell lines. In DU-145, two mutations were found in the p53 gene. A mutation at codon 274 (pro > leu) and a second mutation at codon 223 (val > phe) were present. PC-3 cells were hemizygous for chromosome 17p. The single copy of the p53 gene had a base pair deletion at codon 138 that generated a frame shift and a new in-frame stop codon at position 169.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8104329     DOI: 10.1002/pros.2990230206

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  72 in total

1.  p53-Independent and -dependent requirements for E1B-55K in adenovirus type 5 replication.

Authors:  J N Harada; A J Berk
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

2.  BRCA1-dependent ubiquitination of gamma-tubulin regulates centrosome number.

Authors:  Lea M Starita; Yuka Machida; Satish Sankaran; Joshua E Elias; Karen Griffin; Brian P Schlegel; Steven P Gygi; Jeffrey D Parvin
Journal:  Mol Cell Biol       Date:  2004-10       Impact factor: 4.272

3.  Targeted comparative RNA interference analysis reveals differential requirement of genes essential for cell proliferation.

Authors:  Yuichi J Machida; Yuefeng Chen; Yuka Machida; Ankit Malhotra; Sukumar Sarkar; Anindya Dutta
Journal:  Mol Biol Cell       Date:  2006-09-06       Impact factor: 4.138

Review 4.  Radiosensitization of prostate cancer by priming the wild-type p53-dependent cellular senescence pathway.

Authors:  Brian D Lehmann; James A McCubrey; David M Terrian
Journal:  Cancer Biol Ther       Date:  2007-08-05       Impact factor: 4.742

5.  Human RecQL4 helicase plays critical roles in prostate carcinogenesis.

Authors:  Yanrong Su; Jarah A Meador; Gloria M Calaf; Luca Proietti De-Santis; Yongliang Zhao; Vilhelm A Bohr; Adayabalam S Balajee
Journal:  Cancer Res       Date:  2010-11-02       Impact factor: 12.701

6.  Inhibition of cyclin-dependent kinase activity and induction of apoptosis by preussin in human tumor cells.

Authors:  T V Achenbach; E P Slater; H Brummerhop; T Bach; R Müller
Journal:  Antimicrob Agents Chemother       Date:  2000-10       Impact factor: 5.191

7.  The novel role of IL-37 in prostate cancer: evidence as a promising radiosensitizer.

Authors:  Vivi A Ding; Ziwen Zhu; Timothy A Steele; Mark R Wakefield; Huaping Xiao; Dean Balabanov; Yujiang Fang
Journal:  Med Oncol       Date:  2017-12-05       Impact factor: 3.064

8.  p21/Cip1 and p27/Kip1 Are essential molecular targets of inositol hexaphosphate for its antitumor efficacy against prostate cancer.

Authors:  Srirupa Roy; Mallikarjuna Gu; Kumaraguruparan Ramasamy; Rana P Singh; Chapla Agarwal; Sunitha Siriwardana; Robert A Sclafani; Rajesh Agarwal
Journal:  Cancer Res       Date:  2009-01-27       Impact factor: 12.701

9.  The prognostic value of p53 and DNA ploidy following radical prostatectomy.

Authors:  C Deliveliotis; A Skolarikos; A Karayannis; V Tzelepis; N Trakas; E Alargof; V Protogerou
Journal:  World J Urol       Date:  2003-07-03       Impact factor: 4.226

10.  Synthetic inhibitors of CDKs induce different responses in androgen sensitive and androgen insensitive prostatic cancer cell lines.

Authors:  J Mad'arová; M Lukesová; A Hlobilková; M Strnad; B Vojtesek; R Lenobel; M Hajdúch; P G Murray; S Perera; Z Kolár
Journal:  Mol Pathol       Date:  2002-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.